TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00976404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA + HIV-rAd5 vaccine
Description: 4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART intensification (raltegravir)
Description: raltegravir 400 mg PO BID for 56 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART intensification (raltegravir)
Description: raltegravir 400 mg PO BID for 56 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART intensification (maraviroc)
Description: maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART intensification (maraviroc)
Description: maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
Study: NCT02196948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Study: NCT03363490

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management program
Description: Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management program
Description: Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuromuscular exercise therapy
Description: The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuromuscular exercise therapy
Description: The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: All four groups of patient will receive two times of health education in the first week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: All four groups of patient will receive two times of health education in the first week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: All four groups of patient will receive two times of health education in the first week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: All four groups of patient will receive two times of health education in the first week.
Study: NCT03046862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1.12 g iv on D1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75mg iv on D1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 iv on D1\& D8 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 iv on D1\& D8 every 3 weeks
Study: NCT03419559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: adoptive cell therapy (ACT) with autologous TIL therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: PD-L1 antagonist monoclonal antibody
Study: NCT01377103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testerone gel
Description: 5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01255436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS text reminders
Description: Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
Study: NCT00557856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
Study: NCT04558294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: A moderate dose of 100 μg LSD will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: A moderate dose of 100 μg LSD will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin Placebo
Description: Mannitol capsules instead of capsules containing Ketanserin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin
Description: A dose of 40 mg Ketanserin will be administered.
Study: NCT00916331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcutaneous indwelling
Description: vacuum drainage is indwelled in subcutaneous layer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraarticular indwelling
Description: vacuum drainage is indwelled in intraarticular space
Study: NCT03016494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155 and DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155 and DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1386 Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1386 Tab.
Study: NCT03683459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemFlow Drug-Eluting Peripheral Balloon Catheter
Description: Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
Study: NCT00711191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody
Description: CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
Study: NCT02035267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection.
Study: NCT04917016

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma B-HCG levels
Description: Blood sample
Study: NCT01817803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide/no spironolactone
Description: furosemide (doubling previous furosemide dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metolazone/no spironolactone
Description: metolazone (add 2.5mg qod)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemid/spironolactone
Description: furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metolazone/spironolactone
Description: metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
Study: NCT00751608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APL180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02309905

Intervention type: DEVICE
Intervention: Telemedicine
Description: Inmates of prisons having telemedicine after implementation of telemedicine
Study: NCT00705952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Diet, exercise and behavioural change intervention.
Study: NCT01107158

Intervention type: BIOLOGICAL
Intervention: Whole blood sampling
Description: Whole blood sampling for SNP polymorphism analysis

Intervention type: BIOLOGICAL
Intervention: Whole blood sampling
Description: Whole blood sampling for SNP polymorphism analysis
Study: NCT02914301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Babyscripts Prenatal App
Description: The use of a mobile digital app to facilitate certain aspects of standard prenatal care.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Mobile App, Usual care
Study: NCT01576900

Intervention type: BEHAVIORAL
Intervention: SyBeMeP (Systemized Behavioural Modification education Program)
Description: * Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~* Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~* During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~* After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education.
Study: NCT00842491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar, cisplatin, capecitabine
Description: Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously
Study: NCT01432925

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical intervention on Buruli ulcer
Description: Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical intervention on Buruli ulcer
Description: Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
Study: NCT03187392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Injectable Product
Description: 3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Topical Cream [LMX]
Description: 3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
Study: NCT03727256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound therapy
Description: Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation application
Description: Group 2, neuromuscular electrical stimulation application;20 mins/session
Study: NCT03544762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FES PET
Description: 18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
Study: NCT04030117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACTIVA Bioactive restoration
Description: Removal of Class II decay in second primary molars and placement of ACTIVA restoration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compomer restoration
Description: Removal of Class II decay in second primary molars and placement of Compomer restoration.
Study: NCT04651842

Intervention type: DEVICE
Intervention: PCI
Description: Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention

Intervention type: DEVICE
Intervention: PCI
Description: Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention

Intervention type: DEVICE
Intervention: PCI
Description: Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
Study: NCT01950130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative IABC
Description: IABP-Insertion upon inclusion into the trial and admission to the ICU
Study: NCT01750229

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Frequency Setting - Sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1200 Hz
Description: Frequency Setting - 1200 Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3030 Hz
Description: Frequency Setting - 3030 Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5882 Hz
Description: Frequency Setting - 5882 Hz
Study: NCT01092546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Flutemetamol
Description: All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
Study: NCT02346721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily
Study: NCT00408200

Intervention type: DRUG
Group type: OTHER
Intervention: propafenone; flecainide; sotalol; dofetilide
Description: Above drugs prescribed per established guidelines for treatment of AF

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency catheter ablation
Description: A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency catheter ablation
Description: A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
Study: NCT00892476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Supplementation
Description: Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
Study: NCT01855061

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity.

Intervention type: PROCEDURE
Intervention: Blood samples
Description: Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).

Intervention type: PROCEDURE
Intervention: Pharmacokinetics
Description: Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).

Intervention type: PROCEDURE
Intervention: Midazolam clearance test
Description: Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
Study: NCT02922647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: suprapubic catheterization
Description: Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral catheterization
Description: Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
Study: NCT02342236

Intervention type: DEVICE
Group type: OTHER
Intervention: cemented or cementless type of hip prothesis

Intervention type: DEVICE
Group type: OTHER
Intervention: cemented or cementless type of hip prothesis
Study: NCT04455815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
Study: NCT02747498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure with circumferential pulmonary vein isolation
Description: We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure with linear ablation in addiction to pulmonary vein isolation
Description: We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
Study: NCT04909281

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-sampling HPV
Description: In this cohort study nested in the organized cervical screening program, all women who had not participated in the organized screening program for at least 10 years in one Swedish county were eligible.
Study: NCT00124514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate
Description: IM injection given monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: IM injection given monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: IM injection given monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: IM injection given monthly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 0.9% normal saline IM injection
Study: NCT01042106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-8658
Description: Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.5, 10, 20, 40 mg orally once daily
Study: NCT00196313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
Description: 1 tablet daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 tablet daily by mouth